Safety and Efficacy of Firmagon® (Degarelix) for Injection

Ferring

Status: Completed

Conditions: Prostate Cancer

Treatments: Drug: degarelix

Study type: Observational

Funder types: Industry

Identifiers

NCT02886598

000260

Details and patient eligibility

About

The purpose of this study is to assess the safety and efficacy of Firmagon® (degarelix) for injection under the conditions of general clinical practice in Korea.

Enrollment: 368 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are eligible for the treatment of Firmagon® (degarelix) for injection according to the approved product label, and Firmagon® (degarelix) treatment decided before study enrolment. Moreover, patient should have not previously received Firmagon® (degarelix) for injection before the study commencement date at each site. - Indication: treatment of advanced, hormone-dependent prostate cancer.

Exclusion criteria

• Patients with previous or concurrent known hypersensitivity to any component of the drug.

Trial design

368 participants in 1 patient group

Firmagon®

Description:

Treatment according to standard clinical practice.

Treatment:

Drug: degarelix